Piper Sandler raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Overweight rating on the shares. The firm thinks Exact Sciences presents a compelling investment opportunity underpinned by the Cologuard franchise and expanding opportunities in Cancerguard and MRD long term. The company can drive volumes through its new first-line screening strategy, Cares Gap, and Rescreens, Piper adds. This is all validated by the recent NCI study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target, added to ‘Tactical Outperform’ list at Evercore ISI
- Exact Sciences price target raised to $65 from $55 at Barclays
- Exact Sciences added to Q4 2025 Tactical Ideas List at Wells Fargo
- Exact Sciences Receives Buy Rating from Bruce Jackson Amid Promising MCED Test Launch and Strong Financial Projections
- Craig-Hallum healthcare/pharma analysts hold analyst/industry conference call